HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL - Free Report) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $42.00 target price on the biotechnology company's stock.
Separately, D. Boral Capital restated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.
Read Our Latest Stock Analysis on AVXL
Anavex Life Sciences Stock Down 5.2 %
NASDAQ AVXL traded down $0.43 during trading hours on Monday, reaching $7.87. The company's stock had a trading volume of 732,654 shares, compared to its average volume of 1,250,825. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44. The company has a market capitalization of $669.11 million, a price-to-earnings ratio of -14.33 and a beta of 0.80. The firm's 50-day moving average price is $8.89 and its 200-day moving average price is $8.37.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities research analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Vermillion Wealth Management Inc. purchased a new stake in Anavex Life Sciences during the fourth quarter valued at $34,000. Tower Research Capital LLC TRC increased its holdings in shares of Anavex Life Sciences by 102.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,708 shares during the last quarter. Orion Capital Management LLC raised its position in shares of Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock valued at $65,000 after buying an additional 10,000 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Anavex Life Sciences in the 3rd quarter valued at about $74,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Anavex Life Sciences by 97.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock valued at $86,000 after acquiring an additional 7,421 shares during the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
